ROZLYTREK: payments to doctors
Payments that named ROZLYTREK as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $839K
- Providers
- 3,296
- Transactions
- 7,756
- Average per transaction
- $108
The per-transaction average — $108 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,296 providers the average total is $255, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $683,249 | 81.4% |
| Genentech, Inc. | $155,756 | 18.6% |